20:07:17 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

T:APLI - APPILI THERAPEUTICS INC. J - https://www.appilitherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
APLI - T  83.00.015·0.021096.00.02+0.00533.360.01110.02  0.02  0.0150.045  0.0112:43:00Jun 2515 min RT 2¢
TSX - T83.00.015·0.021096.00.01555.8170.02  0.02  0.0150.045  0.0112:26:5115 min
Omega - O 0.02+0.00533.32.010.02  0.02  0.0211:28:1915 min
CX2 - H 0.02+0.00533.32.010.02  0.02  0.0212:43:0015 min
CXD - D 0.0150.081    Apr 0415 min
TriAct - M 0.0150.11    Sep 11/2015 min

Recent Trades - Last 10 of 11
Time ETExPriceChangeVolumeBuyerSellerMarkers
12:43:00H0.020.0052,00080 National Bank1 AnonymousK
12:26:51T0.015 21,0007 TD Sec19 DesjardinsK
12:26:51T0.015 29,00079 CIBC19 DesjardinsK
12:02:36T0.015 4,0007 TD Sec7 TD SecK
11:28:19O0.020.0052,00019 Desjardins1 AnonymousK
10:33:08T0.0150.0052007 TD Sec1 Anonymous
10:02:23D0.020.00580124 Questrade7 TD SecE
09:46:58M0.020.0051001 Anonymous2 RBCE
09:30:00T0.020.0055007 TD Sec7 TD Sec
09:30:00T0.020.0051,0007 TD Sec7 TD SecKL

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2025-06-25 20:49C:APLI0.015SEDAR Annual Information FormSEDAR Annual Information Form
2025-06-25 20:39C:APLI0.015SEDAR MD & ASEDAR MD & A
2025-06-25 20:26C:APLI0.015SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2025-06-25 18:04C:APLI0.015News ReleaseAppili Therapeutics Reports Fiscal Year 2025 Financial and Operational Results
2025-05-30 16:19C:APLI0.015News ReleaseAppili terminates arrangement with Aditxt
2025-05-20 02:24C:APLI0.03News ReleaseAppili to receive termination fee from Aditxt
2025-05-01 07:34C:APLI0.03News ReleaseAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to Tularemia
2025-04-28 17:47C:APLI0.03News ReleaseAppili Therapeutics granted patents in U.S., Mexico
2025-04-02 17:23C:APLI0.03News ReleaseAppili president to join Aditxt's April 4 update
2025-03-18 17:35C:APLI0.035News ReleaseAppili Therapeutics submits U.S. funding applications
2025-02-14 17:59C:APLI0.03SEDAR Interim MD & ASEDAR Interim MD & A
2025-02-14 17:53C:APLI0.03SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2025-02-14 17:06C:APLI0.03News ReleaseAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025
2024-12-12 08:15C:APLI0.035News ReleaseAditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
2024-11-19 16:31C:APLI0.03News ReleaseAppili receives final court order for Aditxt deal
2024-11-14 08:35C:APLI0.035SEDAR Interim MD & ASEDAR Interim MD & A
2024-11-14 08:29C:APLI0.035SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-11-14 07:15C:APLI0.035News ReleaseAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
2024-11-08 08:30C:APLI0.04News ReleaseAditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
2024-11-07 08:30C:APLI0.035News ReleaseAditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders